nach oben

Erschienen in:

12.03.2020 | Clinical trial

Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy

verfasst von: Theodore S. Jennaro, Fang Fang, Kelley M. Kidwell, Ellen M. Lavoie Smith, Kiran Vangipuram, Monika L. Burness, Jennifer J. Griggs, Catherine Van Poznak, Daniel F. Hayes, N. Lynn Henry, Daniel L. Hertz

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Approximately 25% of patients receiving weekly paclitaxel for breast cancer require treatment disruptions to avoid severe, irreversible peripheral neuropathy (PN). Vitamin insufficiencies are PN risk factors in many diseases, but their relevance to chemotherapy-induced PN is unknown.

Methods

We investigated whether baseline insufficiency of vitamin D, vitamin B12, folate, or homocysteine increased PN in patients with breast cancer receiving weekly paclitaxel in a retrospective analysis of a prospective observational study. Patient-reported PN was collected at baseline and during treatment on the Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (CIPN20). The primary analysis tested associations between vitamin deficiency and the maximum increase from baseline in the CIPN20 sensory subscale (ΔCIPN8). Secondary analyses tested for association with PN-induced treatment disruptions and adjusted associations for treatment and clinical variables.

Results

25-hydroxy-vitamin D was the only nutrient with sufficient deficiency (< 20 ng/mL) for analysis (15/37 = 41%). Vitamin D-deficient patients had a greater mean PN increase than non-deficient patients (ΔCIPN8 ± SD, 36 ± 23 vs. 16 ± 16, p = 0.003) and a non-significant, approximately threefold increase in risk of treatment disruption (OR 2.98, 95% CI [0.72, 12.34], p = 0.16). In multivariable models adjusted for clinical and treatment variables, baseline vitamin D level was inversely associated with PN (β = − 0.04, p = 0.02).

Conclusion

Pre-treatment vitamin D deficiency was associated with PN in women receiving weekly paclitaxel for breast cancer. Vitamin D deficiency may be an easily detected PN risk factor that could be resolved prior to treatment to prevent PN, avoid treatment disruptions, and improve treatment outcomes.

Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (London, England) 379(9814):432–444

Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649PubMed

U.S. Department of Health and Human Services (2010) Common terminology criteria for adverse events (CTCAE) Version 4.0. NIH, Bethesda, MD

Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774PubMed

Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG et al (2018) Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology/NSABP B-30. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx162 CrossRefPubMed

Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer (Oxford, England: 1990) 42(1):24–30

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967PubMed

Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M et al (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132–138PubMed

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M et al (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 20(12):3355–3364PubMed

10.

Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–240PubMed

11.

Kim WY, Woo SU, Seo JH, Son GS, Lee JB, Bae JW (2011) Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther 7(4):412–415PubMed

12.

de Morree ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M et al (2017) Association of Survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study. JAMA Oncol 3(1):68–75PubMed

13.

Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T, Zielinski C, von Minckwitz G (2011) Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 11:131PubMedPubMedCentral

14.

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N et al (2009) Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve 39(1):116–125PubMed

15.

Chopra K, Tiwari V (2012) Alcoholic neuropathy: possible mechanisms and future treatment possibilities. Br J Clin Pharmacol 73(3):348–362PubMed

16.

Reynolds EH (2014) The neurology of folic acid deficiency. Handb Clin Neurol 120:927–943PubMed

17.

Leishear K, Boudreau RM, Studenski SA, Ferrucci L, Rosano C, de Rekeneire N, Houston DK, Kritchevsky SB, Schwartz AV, Vinik AI et al (2012) Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. J Am Geriatr Soc 60(6):1057–1063PubMedPubMedCentral

18.

Lv WS, Zhao WJ, Gong SL, Fang DD, Wang B, Fu ZJ, Yan SL, Wang YG (2015) Serum 25-hydroxyvitamin D levels and peripheral neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis. J Endocrinol Invest 38(5):513–518PubMed

19.

Qu G-B, Wang L-L, Tang X, Wu W, Sun Y-H (2017) The association between vitamin D level and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: an update systematic review and meta-analysis. J Clin Transl Endocrinol 9:25–31PubMedPubMedCentral

20.

Armstrong T, Almadrones L, Gilbert MR (2005) Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 32(2):305–311PubMed

21.

Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, Treisman J, Masri M, Berenson JR (2016) Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer 24(7):3105–3110PubMed

22.

Grim J, Ticha A, Hyspler R, Valis M, Zadak Z (2017) Selected risk nutritional factors for chemotherapy-induced polyneuropathy. Nutrients 9(6):535PubMedCentral

23.

Clement Z, Ashford M, Sivakumaran S (2011) Vitamin D deficiency in a man with multiple myeloma. N Am J Med Sci 3(10):469–471PubMedPubMedCentral

24.

Schloss JM, Colosimo M, Airey C, Vitetta L (2015) Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. Support Care Cancer 23(7):1843–1850PubMed

25.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF et al (2018) Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy. Clin Cancer Res 24(15):3602–3610PubMedPubMedCentral

26.

Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, Henry NL, Stringer KA, Hertz DL (2018) Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 171(3):657–666PubMedPubMedCentral

27.

Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL et al (2018) Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. Pharmacogenomics 20(2):95–104PubMedPubMedCentral

28.

Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (Oxford, England: 1990) 41(8):1135–1139

29.

Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22(10):2787–2799PubMedPubMedCentral

30.

Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK (2017) Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Qual Life Res 26(11):2999–3010PubMed

31.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ et al (2014) Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 106(5):1–11

32.

Annweiler C, Schott AM, Berrut G, Chauviré V, Le Gall D, Inzitari M, Beauchet O (2010) Vitamin D and ageing: neurological issues. Neuropsychobiology 62(3):139–150PubMed

33.

Elf K, Askmark H, Nygren I, Punga AR (2014) Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies. J Neurol Sci 345(1–2):184–188PubMed

34.

Yesil H, Sungur U, Akdeniz S, Gurer G, Yalcin B, Dundar U (2018) Association between serum vitamin D levels and neuropathic pain in rheumatoid arthritis patients: a cross-sectional study. Int J Rheum Dis 21(2):431–439PubMed

35.

Agmon-Levin N, Kivity S, Tzioufas AG, Lopez Hoyos M, Rozman B, Efes I, Shapira Y, Shamis A, Amital H, Youinou P et al (2012) Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren's syndrome. J Autoimmun 39(3):234–239PubMed

36.

Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C et al (2017) Supplement use and chemotherapy-induced peripheral neuropathy in a Cooperative Group Trial (S0221): the DELCaP study. J Natl Cancer Inst 109(12):1–8

37.

Shehab D, Al-Jarallah K, Abdella N, Mojiminiyi OA, Al Mohamedy H (2015) Prospective evaluation of the effect of short-term oral vitamin d supplementation on peripheral neuropathy in type 2 diabetes mellitus. Med Princ Pract 24(3):250–256PubMedPubMedCentral

38.

Alam U, Fawwad A, Shaheen F, Tahir B, Basit A, Malik RA (2017) Improvement in neuropathy specific quality of life in patients with diabetes after vitamin D supplementation. J Diabet Res 2017:7928083

39.

Schloss JM, Colosimo M, Airey C, Masci P, Linnane AW, Vitetta L (2017) A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer 25(1):195–204PubMed

40.

Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19(11):1769–1777PubMed

41.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L et al (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633PubMedPubMedCentral

42.

Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478–3483PubMed

43.

Loven D, Levavi H, Sabach G, Zart R, Andras M, Fishman A, Karmon Y, Levi T, Dabby R, Gadoth N (2009) Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur J Cancer Care 18(1):78–83

44.

Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30(5):733–743PubMed

45.

Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, Gluud C (2014) Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev 6:Cd007469

46.

Bolland MJ, Grey A, Avenell A (2018) Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol 6(11):847–858PubMed

47.

Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, Yelangi A, Sundus S, Bachuwa G, Alkotob ML et al (2019) Vitamin D Supplementation and cardiovascular disease risks in more than 83000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2019.1870 CrossRefPubMed

48.

Schneider BP, Shen F, Jiang G, O'Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA et al (2017) Impact of genetic ancestry on outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00059 CrossRefPubMedPubMedCentral

49.

Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24(6):1472–1478PubMedPubMedCentral

50.

Harris SS (2006) Vitamin D and African Americans. J Nutr 136(4):1126–1129PubMed

Titel: Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy
verfasst von: Theodore S. Jennaro
Fang Fang
Kelley M. Kidwell
Ellen M. Lavoie Smith
Kiran Vangipuram
Monika L. Burness
Jennifer J. Griggs
Catherine Van Poznak
Daniel F. Hayes
N. Lynn Henry
Daniel L. Hertz
Publikationsdatum: 12.03.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05584-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study

Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Outcomes of primary endocrine therapy in elderly women with stage I–III breast cancer: a SEER database analysis

Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases

The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie